<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR14">
 <label>14.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Horstmann</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>McCabe</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Grochow</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Rubinstein</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Budd</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Shoemaker</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Emanuel</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Grady</surname>
    <given-names>C</given-names>
   </name>
  </person-group>
  <article-title>Risks and benefits of phase 1 oncology trials, 1991 through 2002</article-title>
  <source>N Engl J Med</source>
  <year>2005</year>
  <volume>352</volume>
  <fpage>895</fpage>
  <lpage>900</lpage>
  <pub-id pub-id-type="doi">10.1056/NEJMsa042220</pub-id>
  <pub-id pub-id-type="pmid">15745980</pub-id>
 </element-citation>
</ref>
